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Abstract A perspective from the innovative industry is
provided in this article about the long awaited legal pro-
posal for a Clinical Trial Regulation (‘‘Proposal’’), adopted
in July 2012. With this Proposal, the European Commis-
sion reacted to a call by all stakeholders for more harmo-
nization and streamlining of the provisions for conducting
clinical trials in the EU. Discrepant approaches between
Member States, a failure to respect legal timelines, and a
lack of formal coordination mechanisms within and
between Member States have resulted in an increased
workload for the industry and contributed to a decline in
Europe’s attractiveness as a place to carry out research and
development. The Proposal introduces a concept whereby
the sponsor makes a single submission of the clinical trial
application dossier to an EU portal, which is followed by a
single assessment based on cooperation between Member
States. A possibility for the sponsor to choose a ‘reporting
Member State’ to take the lead on key aspects of the
assessment is expected to support excellence building and
work sharing of Competent Authorities in the EU. The
Proposal respects the fact that certain aspects need to be
reviewed nationally. The new process aims to lead to a
single decision per clinical trial per concerned Member
State. The rules are built on the principle of strict adher-
ence to timelines for authorization. The timelines are
ambitious but at the same time competitive, as the process
builds in mechanisms that strengthen compliance. The
rules have been designed to encourage sponsors to file
complete submission packages, since any substantial
modification to a trial would lead to delays in its com-
mencement. Sponsors need to streamline their internal
processes accordingly. In the end, streamlining is an effort
that needs to be accepted by all parties involved. The
Proposal does not detail how Member States organize the
involvement of different bodies, such as Competent
Authorities and Ethics Committees, because according to
the EU Treaty, the EU cannot legislate on aspects falling
into pure Member State competence. The Proposal, how-
ever, establishes the assessment objectives on the basis of
Good Clinical Practices set by the International Conference
on Harmonisation (ICH) and the Declaration of Helsinki by
the World Medical Association. As such, the new legisla-
tion is likely to have implications on Member States’
internal organization. In addition, Ethics Committees in
Europe would benefit from an EU platform for best prac-
tice exchange—a concept that would need to be requested
by the Council and the European Parliament through the
legislative process. A single decision system for the entire
EU per clinical trial has been discussed as an option, but
such an approach was difficult to achieve while respecting
national competencies. In this situation, the Proposal rep-
resents an acceptable compromise, provided its proposed
mechanisms, processes, and timelines are retained upon
implementation. As the Proposal is now on the table for
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discussion by the 27 Member States’ governments and by
the European Parliament, co-legislators and stakeholders
should be aware that any dilution of these provisions would
be detrimental to the objective to ensure patient access and
make the conditions for clinical research in Europe
attractive and fit for the future.
1 Introduction
Innovation is a pillar of the EU’s growth strategy [1]. It is
essential that legislation affecting innovative sectors, such as
the pharmaceutical industry, reflects this. The revision of the
Clinical Trials Directive (‘‘Directive’’) [2] is an opportunity
to improve regulations that are central to pharmaceutical
research and thus patients’ access to innovative medicines.
The Directive’s main purposes are to protect participants
in clinical trials, ensure the trial’s ethical soundness, guar-
antee reliable data, and harmonize administrative aspects
for clinical trials to facilitate cost-efficient clinical research.
Divergent national implementation of the Directive
(applicable from 2004) has led to delays in starting trials
and to increased costs and administrative burden for trial
sponsors and authorities [3–6]. This has contributed to a
steady decline in trials performed in the EU (a 25 % drop
in EU clinical trial applications between 2007 and 2011)
[7] and is threatening Europe’s competitiveness as inves-
tors may seek more favorable locations [8, 9].
Many stakeholders including regulators [10–12], aca-
demics [4–6], and patients [5, 13] recognized that the
legislation contained some fundamental flaws. It is poten-
tially the most criticized piece of all the EU medicines
legislation [14]. Consequently, the European Commission
identified the Directive as a key priority in its flagship
initiative to reduce the administrative burden stemming
from EU legislation [15]. It adopted a legal Proposal for a
Clinical Trial Regulation (‘‘Proposal’’) on 17 July 2012,
which will be discussed by the European Parliament and
the Council of the EU (EU Member States) [7].
This article examines the proposed submission, assess-
ment, and decision-making process for clinical trials, from
an innovative company’s perspective.
2 Challenges of the Existing System
The Directive that governs clinical research in the EU is
very complex. Multiple submissions of common docu-
ments as well as country-specific information to Member
State Competent Authorities and Ethics Committees are
needed to start a trial [4, 5, 16]. These processes run mostly
in isolation.
The industry has noted that the assessment time to get
the authorization to conduct a multinational trial can take
as long as 140–301 days compared with the 60-day time
limit in the current Directive [17].
A complex system by which ‘single’ Ethics Committee
opinions are often based on those of several local com-
mittees (of which there are nearly 1,000 in the EU [18])
may have contributed to this situation [3, 8, 9, 16, 19].
Since a Directive sets only basic requirements at EU
level, it does not provide a sufficient level of harmonization
[16].
3 Seeking a Remedy
3.1 Stakeholder Dialogue
The Commission’s preparations for the legislative Proposal
included meetings and public consultations [8, 20, 21] with
stakeholders and a report about the impact of European
legislation on clinical research [3]. Details around these
constructive efforts from 2004 to 2011 are outside the
scope of this article; however, the view that the Directive is
not functioning properly has been shared by the pharma-
ceutical industry, small- to medium-sized enterprises
(SMEs), academia, and patient organizations.
One policy option discussed during this process was a
centralized coordination and assessment by the European
Medicines Agency (EMA) that would result in an EU-wide
decision, applicable immediately in all Member States [22].
Despite a call from the European Federation of Pharma-
ceutical Industries and Associations (EFPIA) the Commis-
sion did not include this option in the Proposal [22].
3.2 Lessons from Voluntary Cooperation
During early talks on the revision of the Directive, stake-
holders discussed the idea of building the future framework
on an ongoing voluntary cooperation procedure that had
been set up between Member States [8, 23–25]. This pro-
cedure appeared to offer the advantage of streamlined,
well-defined, and common scientific processes [24] and
strict adherence to timelines, based on experience from a
limited number of cases. However, since it was voluntary
and had no legal basis, countries could choose not to par-
ticipate, which may result in uncertainties for overall
clinical development. It also did not address the Ethics
Committee reviews, or how to add countries to the trial,
which was impractical [23].
The proposed Regulation builds on some of the princi-
ples of the voluntary cooperation procedure while
attempting to improve upon its weaknesses.
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4 Proposed Regulation
The main concept of the Proposal is that of strictly
enforced timelines and complete inputs, from authorities as
well as from sponsors.
Another key principle introduced is risk proportional-
ity. The assessment process would take into account the
type of intervention and the extent of knowledge/prior
experience with the investigational medicinal product
(IMP)—particularly whether or not it is authorized in the
EU. The provisions on assessment timelines for adding a
new country to a trial, safety reporting, conduct of the
trial, labeling, and insurance indemnification are likewise
risk-adapted.
The new rules are expected to apply at the earliest from
2016. During a 3-year transition phase, many provisions in
the old Directive and the new Regulation would apply in
parallel [26].
The scope of the Regulation covers interventional clin-
ical trials of medicinal products for human use. Trials
requiring no intervention (such as where the research
subject is not given a medicine) are excluded.
4.1 Submission of a Clinical Trial Application Dossier
with Two Distinct Parts
The Commission proposes a clear delineation between the
EU elements of the sponsor’s application dossier (Part I)
and aspects ‘‘of an intrinsic ethical or national/local nat-
ure’’ [7] (Part II) (Fig. 1):
• Part I containing ‘general’ scientific/technical data
that would be standardized for all Member States
concerned
• Part II containing national, ethical, and local informa-
tion (e.g., investigator suitability, insurance) for each
concerned Member State
The application dossier and all trial-related information
would be submitted to an EU portal linked to a public
database and managed by the Commission [7]. Clinical
trial data would—as a general rule—be publicly accessible
unless confidentiality is justified on specific grounds such
as the protection of commercially confidential information
and personal data [7].
4.2 Assessment
4.2.1 Increased Cooperation Between Countries
and Adherence to Timelines
The Proposal is based on two key principles: ‘a single
decision’ per country and adherence to timelines, meaning
that each Member State is responsible for reaching a
decision on whether to authorize the clinical trial, within a
set time frame.
Each Member State will decide how it organizes itself to
reach this decision, which shall be based on an assessment
of scientific, technical, national, and ethical aspects. While
the EU sets conditions for the assessment, e.g., involve-
ment of patients and the absence of conflicts of interest, it
is not entitled to adopt rules on who—Competent
Authorities or Ethics Committees—in a Member State
assesses which aspect of a trial application.
The Proposal would facilitate European cooperation
through the Clinical Trials Coordination and Advisory
Group (CTCAG) comprised of national contact points,
which would be set up to address conceptual issues that
may arise during the authorization procedure [7].
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4.2.2 A Process Where One Member State Takes the Lead
Although the final decision to authorize a trial lies with
each individual Member State, the Commission proposes
that the sponsor name a ‘reporting Member State’ to lead
the scientific, technical, and benefit–risk aspects of the
assessment. If the Member State does not wish to take on
this role, it can offer the responsibility to other Member
States. If there are no candidates, however, the Member
State proposed by the sponsor is obliged to assume the
responsibility of the reporting Member State.
The reporting Member State assesses Part I and prepares
a report with conclusions. This is generally expected to be
accepted by other concerned Member States (Fig. 2),
which would have the opportunity to ask questions. All
such questions are channeled through the reporting Mem-
ber State, which contacts the sponsor via the portal. The
need for a further coordination mechanism to facilitate
input from Member States on Part I is likely to be subject
to debate as the Proposal moves through the EU legislative
process.
As for Part II, each concerned Member State assesses it
individually and is allowed, ‘‘with justified reasons’’ [7], to
request explanations from the sponsor within a predefined
period.
4.3 Ethics Committees
Ethical aspects of a clinical trial include, for example, the
process and documents to collect informed consent. The
Proposal includes, for the first time, clear references to
universal ethical principles that shall guide conduct of a
trial: the International Conference on Harmonisation (ICH)
Good Clinical Practice (GCP) guidelines and the World
Medical Association’s Declaration of Helsinki—Ethical
Principles for Medical Research Involving Human
Subjects.
The actual ethical assessment will continue to be han-
dled at national level. Each Member State decides how to
organize itself to perform it. The assessment must be car-
ried out within the time frame that applies to the applica-
tion. They may introduce national procedures or legislation
on the mandate and organization of Ethics Committees and
Competent Authorities. Depending on the country, there
may be one national Ethics Committee involved or a larger
network of several local Ethics Committees.
There is no mechanism proposed to guide the func-
tioning of Ethics Committees or to support systematic
cooperation between them. Thus there is no EU forum for
information/best practice exchange that may help reduce
duplication of work.
Fig. 2 Proposed clinical trial
authorization process
(simplified). MS Member State,
w/wo with/without
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4.4 Decision
Conclusions of the reporting Member State on Part I would
generally be accepted by other Member States, which
would only be able to disagree with the conclusions on two
grounds:
• Significant differences in normal clinical practice
compared to that in the reporting Member State
• Infringement of national legislation restricting the use of
human or animal cells and national legislation on drugs
containing, consisting of, or derived from such cells
This is called the ‘qualified opt out’ and obliges the
Member State to communicate its disagreement and a
detailed scientific and socioeconomic justification to the
Commission, all Member States, and the sponsor (Fig. 2).
Each concerned Member State would give one single
decision on the trial’s authorization or rejection through the
EU portal. If the Member State fails to transmit its decision
within the specified timelines, the reporting Member
State’s conclusion on Part I of the assessment report would
be considered as accepted. According to the Commission,
this mechanism should ensure compliance with assessment
timelines [7].
4.5 Changes to a Clinical Trial: Pre- and Post-approval
The procedures assessing changes to a trial are not con-
sistent under the current Directive. According to the Pro-
posal, a change to a trial application may only be submitted
by the sponsor before the assessment on Part I of the initial
submission has been communicated. This approach aims to
discipline sponsors to ensure accuracy and completeness of
their initial application when it is first submitted.
In line with the proposed risk-adapted approach, ‘sub-
stantial’ modifications to an already authorized clinical trial
would undergo an authorization similar to that of the initial
procedure. ‘Substantial’ modifications are changes that have
a substantial impact on the safety or rights of the subjects, or
on the reliability and robustness of the data generated [7].
Modifications to a clinical trial that are not ‘substantial’
would not require additional authorization.
5 Is the Legal Proposal Fit for Purpose?
Viewpoints of an Innovative Company
The Proposal aims to make the clinical trial assessment
system in the EU more benefit–risk based and the autho-
rization processes more effective and less bureaucratic,
while still maintaining a high level of patient protection. It
reflects the Commission’s efforts to consider the different
needs of many stakeholders, namely patients, academia,
healthcare professionals, and the pharmaceutical industry.
In the following sections, the perspective of an innovative
healthcare company is given on how the Proposal meets its
goals and what improvements are still needed to make it a
success.
5.1 How to Make the New Assessment System
a Success in Reality
The Proposal is a major step forward. In particular, the
introduction of a system where decisions are made
according to the principle of respect and adherence to
clearly set review timelines has great potential to make the
clinical trial authorization process much more effective.
These concepts must be kept intact in the final law. It is
essential that Europe regains its attractiveness as a place to
conduct clinical research in the future, especially in the
face of stronger competition than ever from world regions
that have managed to create effective regulatory systems
for clinical trials.
The proposed system has the built-in flexibility to still
allow Member States to carry out expedited assessments of
single-country trials if they choose to do so [7].
The pharmaceutical industry supports [27] the concept
of a ‘reporting Member State’ (see Sect. 4.2.2) taking a
coordinating role. It has the potential to enhance compe-
tition and reinforce the establishment of centers of excel-
lence amongst Competent Authorities in Member States
[28].
Subsequent trials on the same new molecular entity
should be able to refer to the existing information in the EU
portal as long as the information has not changed. This
reduces repetitive submissions.
It is recognized that to comply with the new require-
ments, the industry needs to review its own processes to
ensure that the initial submission packages are complete
and up-to-date (see Sect. 4.5), as failure to provide this
could result in delays in starting trials. There is a high
likelihood this will require significant internal coordination
efforts within globally acting pharmaceutical companies.
In conclusion, to make the proposed streamlined pro-
cedures happen in practice, efforts by national authorities
and Ethics Committees on one side and clinical trial
sponsors on the other side will be required.
5.2 What is Needed to Ensure Legislation is Flexible
for the Future?
Innovative healthcare companies are testing new possibil-
ities such as recruitment via social media and remote
patient participation. Clinical research leading to person-
alized healthcare and advanced therapies, as well as new
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endpoints such as patient-reported outcomes, will influence
clinical trials designs and approaches in future.
The future legal framework must actively support the
assessment of joint clinical trials on personalized health-
care solutions such as a drug and companion diagnostic. It
should not be administratively cumbersome or more com-
plex to conduct such trials. Today, this is a real challenge
as different regulatory frameworks exist for drugs and
companion diagnostics.
This reality demands a regulatory framework that is
flexible enough to adapt to technological advances.
Therefore, the Regulation should be assessed every
5 years. The innovative industry would like to maintain an
ongoing close dialogue with policy makers and legislators
about advances in clinical research (purposes and methods)
with the goal of contributing to a regulatory framework that
is truly fit for purpose.
5.3 What Can Be Done to Further Strengthen
the Ethics Review Processes?
The Commission’s decision to explicitly transfer key eth-
ical principles, guiding the assessment of clinical trials,
from the introductory section of the law into the actual
provisions is a positive development. The ICH GCP
guidelines and the World Medical Association’s Declara-
tion of Helsinki—Ethical Principles for Medical Research
Involving Human Subjects must be followed by all phar-
maceutical companies and applied when designing, con-
ducting, recording, and reporting on clinical trials inside
and outside the EU. The more prominent placing of these
principles in the proposed Regulation is promising.
There is an unfortunate misunderstanding in the medical
community that the Proposal weakens the ethical assess-
ment of clinical trials. As explained above, on the contrary,
it strengthens the ethical aspect through references to
common ethical standards.
While it is understood that further legislation on Ethics
Committees falls under Member States’ exclusive compe-
tence, the industry would be supportive of further cooper-
ation and harmonization across the EU. In a modern
regulatory framework that is moving towards universally
defined principles for ethical assessment, it is essential to
ensure that the decision processes are likewise adjusted to
this international dimension.
A system where national Ethics Committees work in
isolation may not be equipped to serve those needs.
Therefore, it would be beneficial to ensure further infor-
mation and best practice exchange and cooperation, at
European level, between local and national Ethics Com-
mittees. This could be achieved by greater networking
opportunities or even by the creation of an EU-funded
platform for Ethics Committees. Discussions may help
Ethics Committees avoid duplication of work, and ensure
that the universal nature of ethical standards is truly
respected in national decision making.
5.4 Could Contract Negotiations Cause Delays
in Trial Commencement?
In addition to the delays in the regulatory assessment (see
Sect. 2), some companies have experienced delays to the
start of clinical trials in large institutions, like universities.
This is partly because the institutions’ contract signature
processes have required additional reviews, by that insti-
tution, on top of the legal requirements. It is well noted that
this is a point for discussion between sponsors and insti-
tutions, and cannot be regulated at European level.
Therefore, institutions should ensure that contracting pro-
cesses remain reasonable to avoid delaying the start of
clinical trials. This aspect should also be regarded in the
legislative and stakeholder debates.
5.5 What Level of Transparency is Needed?
The principle of transparency must also apply to the
pharmaceutical field to ensure that each stakeholder can
take informed decisions in the EU.
The publication of results of clinical studies is currently
subject to debate by the public, companies, and the EMA.
The Proposal addresses some aspects of this theme, such as
submission, decision, and information on inspection plan-
ning, through the EU database.
In line with EU access to documents legislation, infor-
mation held by the EU institutions may be made available,
unless publication would undermine commercial interests
of companies and the privacy of individuals. Therefore,
guidance is needed, based on an open stakeholder discus-
sion, on what constitutes commercially confidential infor-
mation and personal protected data in the envisaged EU
database on clinical trials, while taking into account the
market authorization status of the product. In general, a
clinical trial application includes a great deal of proprietary
information, such as preclinical and manufacturing data but
no unpublished clinical trial results. Owing to the primarily
confidential nature of the application, establishing the
transparency will be a challenge.
5.6 Are Provisions for Clinical Trials in Third
Countries Sufficient?
Innovative companies are committed to applying the
highest ethical and regulatory standards to serve the needs
of global patient population. Companies are obliged to
perform clinical trials to address needs of local or regional
patient populations in third countries (i.e., countries outside
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the EU/European Economic Area) [29] if they plan to
apply for marketing authorizations in these countries and
have adopted standards. However, there are limitations on
how far EU legislators can support international conditions
in third countries since any such regulation is outside their
remits. In the EU, any clinical trial report which is sub-
mitted with an application for a marketing authorization
needs to have been conducted in accordance with ICH
GCP. According to the Proposal, the Commission plans to
conduct controls and inspections in third countries to verify
that the international standards are indeed applied and
complied with in those countries. Existing initiatives, such
as by the European and Developing Countries Clinical
Trials Partnership Programme (EDCTP), must be contin-
ued and enhanced, to ensure that international standards are
implemented in practice in these countries to respect the
specific vulnerability of patients there.
6 Across the Atlantic
Given the global nature of clinical trials, regions use their
systems and regulations to compete for research invest-
ment. Companies often report that in the USA, investiga-
tional new drug applications for a particular trial are
cleared in 30 days by the Food and Drug Administration
(FDA). Ethics approvals by the US equivalent of Ethics
Committees, Institutional Review Boards (IRBs), are also
obtained faster than in the EU. This has resulted in earlier
initiation of clinical trials and earlier access to investiga-
tional drugs in the USA [17].
The regulation of IRBs has been under increasing
scrutiny in recent years. The system has been criticized for
‘‘not adequately calibrating the review process to the risk
of research’’ [30]. The FDA is therefore planning to change
its regulations and streamline the review of multi-site
studies.
7 Conclusion
Streamlined processes for clinical trial authorizations are
essential for the innovative industry to conduct effective
clinical research with the goal of developing treatments for
patients. The ideal scenario would be one single submis-
sion, assessment, and decision for the conduct of a trial in
all EU Member States. Owing to the complexity of the EU
jurisdiction in relation to national jurisdictions and cultural
aspects, such a truly harmonized system would be chal-
lenging to achieve in the EU but should be the long-term
goal. That said, the Proposal already offers a vast
improvement over the current situation. Emphasizing
common objectives and adherence to clear timelines, it
provides for maximum coordination between Member
States and implies a streamlining of national cooperation of
authorities and Ethics Committees. In line with these goals,
Ethics Committees should be offered an EU-funded plat-
form for best practice exchange.
Sponsors, on their side, need to be prepared to submit
comprehensive, complete application dossiers since sub-
stantial modifications may prolong the procedure. This may
require readjustment of processes within global companies.
The reinforced focus on adherence to timelines and the
updated assessment concepts must be supported by stake-
holders as the Proposal moves through the EU legislative
process. All parties involved in the conduct of clinical trials
must be ready to adapt to future changes, in the interest of
effective assessment of ethical and safety aspects of trials,
patient access to treatment, and the EU’s competitiveness.
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